CD274 and non-small cell lung carcinoma: Our results indicate that in patients with advanced NSCLC who have high levels of PD-L1 expression, the combination of pembrolizumab and chemotherapy is more efficacious than pembrolizumab alone as the first-line therapy in terms of PFS (median survival time: 10.41 months versus 7.41 months) and ORR (RR:1.74).